ANGLE plc (GB:AGL) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
